CLO investors on Monday said that they were pleased with the decision by Valeant Pharmaceuticals to appoint Joseph Papa as CEO, adding to the good news in recent weeks as to the direction of the embattled Canadian drug company.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Sam Kerr